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The most common seizure disorder in children is
febrile convulsion (FC), which occurs in 1–10% of
children [1]. Neuropeptide Y (NPY), which is widely
distributed throughout the central nervous system,
including the hippocampus, is known to prevent
seizures in rats [2]. Woldbye et al observed that NPY
administered through the lateral ventricle of rats
inhibited kainic acid-induced motor and electroen-
cephalographic seizures [3]. Dubé et al also found that
endogenous NPY prevented experimentally induced
seizures in rats by increasing the seizure threshold
[4]. NPY receptor knockout mice have also been shown
to be sensitive to kainic acid-induced seizures [5].
Taken together, these animal studies suggest that
NPY is critical in modulating the excessive synaptic
excitation associated with an epileptic seizure.
However, the relationship between NPY and FC has
not been established in humans. In a previous study,
we found that plasma concentrations of NPY may 
be lower in patients with atypical FC than those 
with typical FC [6]. To test our hypothesis, we per-
formed this observational study to further investi-
gate the role of plasma NPY concentrations in children
with typical FC, atypical FC and age-matched 
controls.
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Febrile convulsion (FC) is the most common neurological disease in children. Cases with seizures
that persist for more than 15 minutes or recurrent seizures within the same febrile illness are con-
sidered to be atypical and may have a different prognosis. Neuropeptide Y (NPY), an endoge-
nous anticonvulsant that is widely distributed throughout the central nervous system, including
the hippocampus, is known to prevent seizures by increasing the seizure threshold. Based on our
previously finding that patients with atypical FC have lower concentrations of NPY, we hypothe-
sized that the concentration of NPY may play a role in the development of atypical FC. To inves-
tigate this hypothesis, we used a radioimmunoassay to measure the plasma NPY concentration
of 60 children with FC (typical FC, n = 46; atypical FC, n = 14) and 56 age-matched controls. The
atypical FC group had significantly lower concentrations of NPY than children with typical FC
and controls (66.47 ± 19.11 pmol/L vs. 88.68 ± 28.50 pmol/L and 86.82 ± 22.66 pmol/L, respec-
tively). Very low NPY levels were found in two patients; one patient (NPY level: 44.75 pmol/L)
experienced prolonged seizures lasting for up to 1 hour and the other had recurrent seizures
(three seizures) during the same febrile illness (NPY level: 33.53 pmol/L). These results suggest
that patients with inadequate NPY inhibitory activity are more susceptible to atypical FC.
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MATERIALS AND METHODS
For this study, we enrolled 60 children who were clin-
ically diagnosed with FC and 56 age-matched controls.
All FC patients met stringent FC criteria based on those
used by Freeman [7]. The children were further clas-
sified into those with either typical FC or atypical FC,
the latter defined as those patients having seizures
persisting for more than 15 minutes, repeated seizures
during the same febrile illness or a focal seizure. Our
controls were recruited from patients who were
admitted to our department for non-FC diseases such
as pneumonia or acute gastroenteritis. A responsible
adult provided written informed consent for each
child. Blood samples were taken from the partici-
pants within 3 days after a seizure and from our con-
trols within 3 days after admission. The protocol for
this study was approved by the Institutional Review
Board of Kaohsiung Medical University Hospital.
Blood samples underwent electrolyte, blood sugar
and gas analysis in the hospital’s clinical laboratory.
Plasma was obtained by centrifugation for 5 minutes
at 3,000 rpm at 4°C and stored at −70°C until required
for the NPY assay.
The plasma concentration of NPY was measured
by radioimmunoassay, as previously described [8].
Briefly, 50 μL of plasma was added to disposable
reverse-phase mini columns (Sep Column; Peninsula
Laboratories Inc., Belmont, CA) and eluted. The
eluted fractions were lyophilized and reconstituted
in radioimmunoassay buffer. The NPY concentration
in each sample was measured using a commercially
available radioimmunoassay (Peninsula Laboratories).
Statistical analysis
Data are shown as mean ± standard error. All statisti-
cal analyses were performed using SPSS version 12.0
(SPSS Inc., Chicago, IL, USA). Two-sample t tests and
χ2 tests were used to compare the means and the pro-
portions between the two groups. A value of p < 0.05
was considered significant.
RESULTS
Forty-six of the 60 patients with FC (76.7 %) had typi-
cal FC and 14 (23.3%) had atypical FC. The mean ages
of the typical and atypical FC patients, and controls,
were 25.98 ± 15.57 months, 31.14 ± 18.48 months and
30.0 ± 14.91 months, respectively. There was no sig-
nificant difference in age between the three groups.
Nineteen FC patients (31.67%) had a family history of
FC. The female-to-male ratio was 1:2.29 for the con-
trol group, 1:1.42 for the typical FC group, and 1:3.66
for the atypical group (Table). Of the 60 patients with
FC, 11 (18.33%) had experienced two or more FC
seizures by the time of our study.
The results of the blood sample analysis showed
no significant differences in the levels of sodium,
potassium or sugar between patients with typical
and atypical FC, although patients with atypical FC
had significantly lower levels of ionized calcium
(4.54±0.39 mg/dL vs. 5.00±0.33 mg/dL, p=0.011) and
acidosis (7.289 ± 0.096 vs. 7.357 ± 0.051, p = 0.041) than
the typical group (Table).
As shown in Figure 1, the NPY concentration was
significantly lower in patients with atypical FC than
in those with typical FC (66.47 ± 19.11 pmol/L vs.
88.68 ± 28.50 pmol/L, p = 0.01) or the control group
(86.82 ± 22.66 pmol/L, p = 0.019). Two of the patients
with atypical FC had particularly severe FC episodes,
with one having experienced a seizure that persisted
for 1 hour and the other having three seizures during
the same febrile illness. The average NPY concentration
Table. Demographic characteristics and clinical laboratory investigations of patients with febrile convulsion*
Typical FC (n = 46) Atypical FC (n = 14) p
Age (mo) 25.98 ± 15.57 31.14 ± 18.48 0.303
Sex (male vs. female) 27:19 11:3 0.175
Family history of FC 13 (28.3) 6 (42.9) 0.306
Na (mmol/L) 135.5 ± 3.0 (n = 40) 135.5 ± 2.8 (n = 10) 1.000
K (mmol/L) 4.26 ± 0.35 (n = 40) 4.40 ± 0.41 (n = 10) 0.292
Ca (mg/dL) 5.00 ± 0.33 (n = 17) 4.54 ± 0.39 (n = 6) 0.011†
Sugar (mg/dL) 113 ± 34 (n = 38) 120 ± 51 (n = 12) 0.582
pH 7.357 ± 0.051 (n = 15) 7.289 ± 0.096 (n = 7) 0.041†
*Data presented as mean ± standard error or n (%); †p < 0.05; FC = febrile convulsion; Na = Sodium; K = Potassium; Ca = Calcium.
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in the two patients with severe atypical FC was 39.14±
7.93 pmol/L (Figure 2), which was lower, although 
of borderline significance, than the levels in other
patients in the atypical FC group (n = 12, p = 0.055).
We compared the differences in NPY levels of the
boys and girls in our FC group (typical and atypical),
and found no significant difference between sexes
(males vs. females, 83.56 ± 26.80 pmol/L vs. 84.73 ±
29.69 pmol/L).
DISCUSSION
In this study, we found a significantly lower plasma
concentration of NPY in patients with atypical FC
than in those with typical FC. The two patients with
prolonged seizures (> 30 minutes) or with more than
two seizures during the same febrile illness had even
lower plasma NPY concentrations.
Several biochemical and electrophysiological
findings in animal models and in tissues from
humans with epilepsy suggest that NPY plays an
important role in suppressing seizures. One study
found that epileptic rats treated with a recombinant
adeno-associated viral vector expressing the human
NPY gene had much fewer seizures than the control
group, an effect that was correlated with overexpres-
sion of NPY in the hippocampus [9]. Two other stud-
ies have suggested that the absence of inhibitory
control by NPY may contribute to epileptogenesis
[10,11]. One animal study of rat models of seizures
revealed that adding agonists of the Y1, Y2, and Y5
NPY receptors to hippocampal cultures reduced
seizure-like activity [12]. In a study of patients with
mesial temporal lobe epilepsy, NPY was found to pos-
sibly mediate the inhibition of glutamate release
through up-regulation of NPY Y2 receptors [13]. Based
on this evidence, it is clear that NPY plays an impor-
tant role in suppressing seizures in epilepsy. Our
study found significantly lower plasma NPY concen-
trations in patients with atypical FC. However, there
was no significant difference in the plasma NPY con-
centration between patients with typical FC and the
control group. It was reported that patients with
atypical FC show increased risk for epilepsy [14].
Therefore, our results suggest that patients with typi-
cal FC and normal NPY concentrations are not at
increased risk of epilepsy. Besides, patients with low
NPY concentrations may be more susceptible to long-
lasting or recurrent seizures and are at higher risk of
developing epilepsy. Accordingly, the concentration
of NPY could be used as a marker to differentiate
between typical and atypical FC.
There is a low possibility that our results could be
confounded by sex because one of our previous stud-
ies and a study by another group have revealed that
the majority of people with FC in Taiwan are male 
[6,15], raising the possibility that gender may play a
role in the pathogenesis of FC. However, our current
study and a study performed by Doniec et al in asth-
matic patients found no differences in plasma concen-
trations of NPY between male and female [16].
Figure 2. Plasma neuropeptide Y levels in two patients with
severe atypical febrile convulsion compared with other patients
with atypical febrile convulsion. FC = febrile convulsions.
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Figure 1. Plasma neuropeptide Y level of patients with atypical
febrile convulsions (n = 14) was significantly lower than in those
with typical febrile convulsion (n = 46) and control group (n = 56).
FC = febrile convulsions.
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Our results might also be confounded by the
imbalance in electrolyte levels. We found that patients
with atypical FC had a lower average ionized cal-
cium level than those with typical FC but, because
the average was within the normal range (reference
value, 4.0–5.5 mg/dL), it is unlikely that the persistent
or recurrent seizures were induced by lower levels of
ionized calcium. We did find a significant difference
in acidosis, a finding similar to another study, which
reported acidosis to be common in patients with sta-
tus epilepticus [17]. These findings suggest that there
might be an association between acidosis in patients
with atypical FC and their prolonged seizures.
One limitation of our study is that we did not ana-
lyze NPY concentrations in cerebrospinal fluid (CSF).
One study of patients under anesthesia reported that
the NPY concentration was much higher in CSF than
in peripheral blood [18]. However, another study
found no association between plasma and CSF con-
centrations of NPY in obese women [19]. Therefore,
the relationship between central and peripheral NPY
remains poorly understood. Because there was no
clinical indication for lumbar tapping in our patients,
we did not analyze the NPY concentration in CSF,
representing a possible limitation or our study. The
association between the central and peripheral NPY
levels will need further investigation. Our finding that
patients with atypical FC have lower of plasma NPY
concentrations than those with typical FC suggests
that low NPY levels renders FC patients more sus-
ceptible to long-lasting seizures or recurrent FC, and
increased the risk for epilepsy, independent of sex.
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非典型熱性痙攣病患具有較低的血漿神經胜肽 Y
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熱性痙攣是小兒科最常見的神經疾患，病患若抽痙超過 15 分鐘或是在同一次發燒疾
患中發生兩次以上的抽痙都被稱為非典型的熱性痙攣，這種非典型的熱性痙攣跟典型
的熱性痙攣通常有不一樣的預後。神經胜肽 Y 是一種內生性的抗痙攣物質，它廣泛的
分布於中樞神經系統包含海馬回中，被認為有增加痙攣的閥值而達到減少痙攣發生的
功用，我們過去的研究發現非典型熱性痙攣病患有較低的血漿神經胜肽 Y 濃度，因此
假設神經胜肽 Y 濃度在非典型熱性痙攣扮演一定的角色，為了證明此一假說，我們用
放射免疫分析來測量 60 個熱性痙攣兒童的血漿神經胜肽 Y 濃度，其中包含 14 個非
典型熱性痙攣及 46 個典型熱性痙攣，並與 56 個年齡相近的對照組做比較。結果顯示
非典型熱性痙攣兒童的血漿神經胜肽 Y 濃度顯著的比典型熱性痙攣兒童及對照組低
(66.47 ± 19.11 pmol/L vs. 88.68 ± 28.50 pmol/L 及 86.82 ± 22.66 pmol/L)，
尤其有兩個非典型熱性痙攣病患血漿神經胜肽 Y 濃度更低 (44.75 pmol/L 及 33.53 
pmol/L)，臨床上，一個痙攣持續一個小時，另一個在同一次的發燒疾患發生三次痙
攣，這些結果表示病患若缺乏足夠的神經胜肽 Y 抑制作用比較容易發生非典型熱性痙
攣。
關鍵詞：熱性痙攣，神經胜肽 Y
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